A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.

MLA

Descamps, G., et al. “A Humanised Anti-IGF-1R Monoclonal Antibody (AVE1642) Enhances Bortezomib-Induced Apoptosis in Myeloma Cells Lacking CD45.” British Journal of Cancer, vol. 100, no. 2, Jan. 2009, pp. 366–69. EBSCOhost, https://doi.org/10.1038/sj.bjc.6604839.

APA

Descamps, G., Gomez-Bougie, P., Venot, C., Moreau, P., Bataille, R., & Amiot, M. (2009). A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. British Journal of Cancer, 100(2), 366–369. https://doi.org/10.1038/sj.bjc.6604839

Chicago

Descamps, G., P. Gomez-Bougie, C. Venot, P. Moreau, R. Bataille, and M. Amiot. 2009. “A Humanised Anti-IGF-1R Monoclonal Antibody (AVE1642) Enhances Bortezomib-Induced Apoptosis in Myeloma Cells Lacking CD45.” British Journal of Cancer 100 (2): 366–69. doi:10.1038/sj.bjc.6604839.